Double positivity of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies enhances both thrombosis and positivity of anti-ADAMTS13 antibody

被引:0
|
作者
Jiwon Yun
JaYoon Gu
Hyun Kyung Kim
机构
[1] Seoul National University College of Medicine,Department of Laboratory Medicine
[2] Cancer Research Institute,undefined
[3] Seoul National University College of Medicine,undefined
来源
关键词
Antiphospholipid antibodies; Thrombosis; β; -glycoprotein I; Phosphatidylserines; prothrombin; ADAMTS13;
D O I
暂无
中图分类号
学科分类号
摘要
Although a few antiphospholipid syndrome (APS) occurs with acquired thrombotic thrombocytopenic purpura (TTP), the relationship between antiphospholipid antibodies (aPL) and anti-ADAMTS13 (anti-a disintegrin and metalloprotease with thrombospondin type 1 motif, member 13) antibody remains uncertain. We investigated the relationship between high-risk thrombotic aPL and anti-ADAMTS13 antibody. Two hundred and thirty-seven patients with positive lupus anticoagulant and/or anticardiolipin antibody were included. Anti-β2GPI (anti-β2-glycoprotein I), anti-β2GPIdI (anti-β2-glycoprotein I domain I), anti-PS/PT (anti-phosphatidylserine and prothrombin), ADAMTS13 activity, and anti-ADAMTS13 antibody were measured. Double positivity of anti-β2GPI and anti-PS/PT increased thrombotic risk more than three-fold and showed increased positivity of anti-ADAMTS13 antibody in comparison with the double negative group. Double positivity of anti-β2GPIdI and anti-PS/PT presented both effects even more. In the linear regression analysis, double positivity of anti-β2GPI and anti-PS/PT independently affected the anti-ADAMTS13 antibody level (β = 1.982, P = 0.042). Our results revealed that double positivity of anti-β2GPI or anti-β2GPIdI and anti-PS/PT increased not only thrombotic risk but also the positivity of anti-ADAMTS13 antibody, especially indicating anti-β2GPIdI showed a higher synergistic effect with anti-PS/PT. We suggest a possible association of anti-ADAMTS13 antibody with a high thrombotic risk of APS.Double positivity of anti-β2GPI (anti-β2-glycoprotein I) and anti-PS/PT (anti-phosphatidylserine and prothrombin) antibodies enhanced not only thrombotic risk but also positivity of anti-ADAMTS13 (anti-a disintegrin and metalloprotease with thrombospondin type 1 motif, member 13) antibody.Furthermore, double positivity of anti-β2GPIdI (anti-β2-glycoprotein I domain I) combined with anti-PS/PT even more elevated both thrombosis and positivity of anti-ADAMTS13 antibody.Double positivity of β2GPI and anti-PS/PT was found as an independently significant contributing factor to anti-ADAMTS13 antibody level.We suggest the association between anti-ADAMTS13 antibody and the pathophysiology of antiphospholipid syndrome, which should be further evaluated.
引用
收藏
页码:1133 / 1136
页数:3
相关论文
共 50 条
  • [21] Concomitant appearance of anti-cardiolipin, anti-β2-glycoprotein I, anti-prothrombin and anti-annexin V antibodies
    S Cucnik
    N Gaspersic
    T Kveder
    B Bozic
    Arthritis Res Ther, 6
  • [22] Concomitant appearance of anti-cardiolipin, anti-β2-glycoprotein I, anti-prothrombin and anti-annexin V antibodies
    Cucnik, S
    Gaspersic, N
    Kveder, T
    Bozic, B
    ARTHRITIS RESEARCH & THERAPY, 2004, 6 (Suppl 1) : S2 - S2
  • [23] COEXISTENCE OF ANTI-BETA2-GLYCOPROATEIN I DOMAIN I AND ANTI-PHOSPHATIDYLSERINE/PROTHROMBIN ANTIBODIES SUGGESTES STRONG THROMBOTIC RISK
    Kim, Hyun Kyung
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 : 57 - 57
  • [24] Pathogenic anti-β2-glycoprotein I antibodies recognize domain I of β2-glycoprotein I only after a conformational change
    de Laat, B
    Derksen, RHWM
    van Lummel, M
    Pennings, MTT
    de Groot, PG
    BLOOD, 2006, 107 (05) : 1916 - 1924
  • [25] Anti-β2-glycoprotein I and anti-prothrombin antibodies in Antiphospholipid-Negative patients with thrombosis -: A case-control study
    Previtali, S
    Barbui, T
    Galli, M
    THROMBOSIS AND HAEMOSTASIS, 2002, 88 (05) : 729 - 732
  • [26] CLINICAL ACCURACY OF ANTI-PHOSPHATIDYLSERINE/PROTHROMBIN AND ANTI-BETA2GLYCOPROTEIN I DOMAIN I FOR PREDICTING CLINICAL MANIFESTATIONS OF ANTI-PHOSPHOLIPID SYNDROME
    Radin, M.
    Cecchi, I.
    Foddai, S. G.
    Rubini, E.
    Barinotti, A.
    Sciascia, S.
    Roccatello, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 895 - 896
  • [27] Anti-β2-glycoprotein I antibodies and systemic lupus erythematosus
    Antolín, J
    Almeida, D
    Amérigo, MJ
    Cantabrana, A
    Roces, A
    Hayeck, M
    MEDICINA CLINICA, 2002, 119 (09): : 331 - 332
  • [28] Clinical significance of anticardiolipin and anti-β2-glycoprotein I antibodies
    Obermoser, G
    Bitterlich, W
    Kunz, F
    Sepp, NT
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2004, 135 (02) : 148 - 153
  • [29] Anti-β2-glycoprotein I antibodies in children with atopic dermatitis
    Ambrozic, A
    Avicin, T
    Ichikawa, K
    Kveder, T
    Matsuura, E
    Hojnik, M
    Atsumi, T
    Rozman, B
    Koike, T
    INTERNATIONAL IMMUNOLOGY, 2002, 14 (07) : 823 - 830
  • [30] Does anti-β2-glycoprotein I antibody provide additional information in patients with thrombosis?
    Lee, EY
    Lee, CK
    Lee, TH
    Chung, SM
    Kim, SH
    Cho, YS
    Yoo, B
    Moon, HB
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S45 - S45